Triplet Regimen Induces Durable Responses in Patients With Treatment-Refractory mCRC
January 22nd 2022Treatment with a triplet combination of pembrolizumab, binimetinib and bevacizumab was associated with an observed clinical benefit in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.
Read More
Pembrolizumab Plus Chemotherapy Represents New SOC for Esophageal Cancer/ GEJ Adenocarcinoma
January 22nd 2022According to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit.
Read More
TACE Plus Lenvatinib and a PD-1 Antibody Appears Safe, Effective in Advanced uHCC
January 21st 2022The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.
Read More
Trastuzumab Deruxtecan Extends Overall Survival in HER2+ Advanced Gastric/GEJ Cancer
January 20th 2022Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
Read More
Responses to Cilta-Cel Durable for Nearly 2 Years Across Several R/R Multiple Myeloma Subgroups
December 15th 2021Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.
Read More